{"gene":"NT5E","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2011,"finding":"NT5E/CD73 converts AMP to adenosine; loss-of-function mutations (nonsense p.S221X, missense p.C358Y, frameshift p.V537fsX7) abolish this enzyme activity and cause arterial and joint calcifications. Cultured fibroblasts from affected patients showed markedly reduced CD73 protein, absent enzyme activity, elevated alkaline phosphatase, and accumulated calcium phosphate crystals. Genetic rescue with wild-type NT5E normalized CD73 and alkaline phosphatase activity; adenosine treatment reduced alkaline phosphatase levels and calcification.","method":"Western blotting, enzyme activity assays, in vitro calcification assays, transduction rescue experiments, SNP analysis, targeted gene sequencing","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (enzyme assay, rescue experiment, in vitro calcification), replicated across three independent families","pmids":["21288095"],"is_preprint":false},{"year":2014,"finding":"Disease-causing NT5E mutations (p.S221X, p.C358Y, p.V537fsX7) result in mistrafficking of NT5E protein away from the plasma membrane: mutant proteins accumulate in the cell synthetic apparatus (ER/vesicles) rather than reaching the cell surface, with reduced ER retention and absent NT5E enzymatic activity at the cell surface.","method":"Confocal microscopy, western blot of fractionated cell constituents, enzyme histochemistry (Malachite green assay), heterologous expression of DsRed-tagged wild-type and mutant NT5E in COS-7 cells","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (subcellular fractionation, confocal imaging, enzymatic assay) in a single focused study","pmids":["24887587"],"is_preprint":false},{"year":1997,"finding":"CD73 functions as a costimulatory molecule for T cell activation independently of its enzymatic activity and independently of its GPI anchor (demonstrated using a Jurkat T cell transfection model); however, expression of p56lck, CD45, and the T cell receptor are required for CD73-mediated T cell activation in vitro.","method":"Jurkat T cell transfection with CD73 cDNA constructs (enzymatic-activity-null and GPI-anchorless mutants), functional T cell activation assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined genetic dissection of enzymatic vs. non-enzymatic function with multiple constructs, single lab","pmids":["9113412"],"is_preprint":false},{"year":2012,"finding":"CD73-generated adenosine promotes osteoblast differentiation via A2B adenosine receptor (A2BAR) signaling. CD73-deficient mice show osteopenia with reduced osteoblastic markers but normal osteoclastic markers. Overexpression of CD73 in MC3T3-E1 cells enhanced osteocalcin and bone sialoprotein expression, an effect blocked by an A2BAR antagonist but not an A2AAR antagonist.","method":"CD73-knockout mouse bone phenotyping, in vitro osteoblast differentiation assays, CD73 overexpression in MC3T3-E1 cells, pharmacological receptor antagonism","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout phenotype corroborated by in vitro gain-of-function and pharmacological dissection of receptor subtype, multiple orthogonal approaches","pmids":["21882189"],"is_preprint":false},{"year":2011,"finding":"NT5E (CD73) and PAP are the principal ectonucleotidases generating adenosine in spinal nociceptive circuits. AMP hydrolysis was nearly abolished in dorsal root ganglia and spinal cord lamina II of Pap/Nt5e double-knockout mice. NT5E rapidly converts AMP to adenosine within seconds in lamina II (measured by fast-scan cyclic voltammetry), and the resulting adenosine inhibits nociception via the A1 adenosine receptor.","method":"Histochemical AMP hydrolysis, fast-scan cyclic voltammetry in spinal lamina II, behavioral nociception assays, Pap/Nt5e double-knockout mice, pharmacological A1 receptor analysis","journal":"Molecular pain","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo knockout combined with real-time electrochemical adenosine measurement and behavioral/electrophysiological readouts, multiple orthogonal methods","pmids":["22011440"],"is_preprint":false},{"year":2015,"finding":"CD73-generated adenosine induces cortical actin polymerization in endometrial epithelial cells via adenosine A1 receptor (A1R) activation of a Rho GTPase CDC42-dependent conformational change of the N-WASP subunit of the ARP2/3 complex. This cortical F-actin elevation increases membrane E-cadherin, β-catenin, and Na+K+ ATPase, maintaining epithelial integrity. Loss of CD73 reduces endometrial epithelial barrier function and increases migration/invasion.","method":"CD73 pharmacological inhibition, CD73 knockout mouse model, in vitro migration/invasion assays, co-localization of CD73 with cell-cell contacts and filopodia, A1R antagonism, Rho GTPase and ARP2/3 pathway analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway dissection with multiple orthogonal approaches (KO mice, pharmacological inhibition, pathway-specific inhibitors), defining A1R→CDC42→N-WASP→ARP2/3 axis","pmids":["26642367"],"is_preprint":false},{"year":2019,"finding":"CD73-derived adenosine activates adenosine A2A receptor (A2AR) in a feed-forward manner in microglia, upregulating CD73 and A2AR to promote neuroinflammation in Parkinson's disease models. CD73 inactivation attenuated LPS-induced pro-inflammatory responses, enhanced microglial process extension and movement, and suppressed microglia-mediated neuroinflammation. A2AR-mediated pro-inflammation was restored by exogenous adenosine analogues.","method":"CD73 inactivation in MPTP mouse model, LPS-stimulated microglia assays, laser injury model, pharmacological adenosine replenishment, morphological analysis of microglia","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro loss-of-function with mechanistic rescue, single lab","pmids":["30689733"],"is_preprint":false},{"year":2017,"finding":"CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned macrophages. Adenosine generated by CD73 (AMP→adenosine) but not CD39 (ATP→AMP) is required for apoptotic cell-driven suppression of TNF in LPS-conditioned macrophages, acting through the adenosine A2a receptor (Adora2a). In mice, CD73 was required to limit neutrophil influx in a peritonitis model.","method":"Enzymatic depletion of adenosine, pharmacological A2a receptor inhibition, CD73-knockout macrophages, RAW264.7 ectopic co-expression of A2a and CD73, in vivo peritonitis model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus pharmacological inhibition plus ectopic expression rescue, multiple orthogonal approaches dissecting CD73-specific (not CD39) requirement","pmids":["28060378"],"is_preprint":false},{"year":2020,"finding":"Tumor-infiltrating NK cells transport CD73 in intracellular vesicles to the cell surface and extracellular space via actin polymerization-dependent exocytosis, triggered by engagement of 4-1BBL on tumor cells. CD73-positive NK cells undergo transcriptional reprogramming with upregulated IL-10 production via STAT3 transcriptional activity, suppressing CD4+ T cell proliferation and IFN-γ production.","method":"Flow cytometry, live cell imaging of CD73-vesicle trafficking, cytokine assays, STAT3 inhibition, functional T cell suppression assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection of vesicle transport and STAT3-IL-10 axis, single lab with multiple methods","pmids":["31770109"],"is_preprint":false},{"year":2019,"finding":"CD73 on glioblastoma endothelial cells promotes tumor invasiveness through A2B adenosine receptor (A2B AR) signaling, which induces matrix metalloproteinase-2 (MMP-2) expression. Inhibition of A2B AR signaling decreased multidrug resistance transporter expression (P-gp and MRP1) and potentiated temozolomide-induced cell death. The CD73-FLK mouse model demonstrated that endothelial CD73 drives tumor invasiveness and brain morphology distortion.","method":"CD73-knockout and CD73-FLK transgenic mouse GBM models, A2B AR inhibition, immunohistochemistry, tumor growth/vessel density measurement","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — spatially-defined genetic models and pharmacological intervention, single lab","pmids":["30926752"],"is_preprint":false},{"year":2023,"finding":"TRIM21 is an E3 ubiquitin ligase that targets CD73 for ubiquitin-mediated proteolytic degradation. Lysine residues K133, K208, K262, and K321 on CD73 are required for TRIM21-mediated ubiquitylation and degradation. Loss of TRIM21 stabilizes CD73, enhancing CD73-catalyzed adenosine production and suppressing CD8+ T cell function, promoting tumor growth.","method":"Co-immunoprecipitation, ubiquitylation assays, site-directed mutagenesis of CD73 lysine residues, TRIM21 knockout/overexpression, CD8+ T cell functional assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct biochemical identification of E3 ligase (Co-IP), mutagenesis of ubiquitylation sites, functional cellular consequences, multiple orthogonal methods","pmids":["36608132"],"is_preprint":false},{"year":2023,"finding":"CD73 deficiency in pancreatic tumor cells leads to increased DNA damage and activation of the cGAS-STING pathway. cGAS expression in tumor cells was required for the antitumor activity of the CD73 inhibitor AB680 in vivo, linking CD73 to suppression of innate immune sensing of tumor DNA damage.","method":"CRISPR/genetic CD73 deletion in mouse KPC tumor cells, cGAS knockout, in vivo tumor models, pharmacogenomic analysis of human PDAC cell lines","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo (cGAS required for CD73 inhibitor effect), complemented by pharmacogenomics, single lab","pmids":["36409930"],"is_preprint":false},{"year":2023,"finding":"CD73 significantly enhances tumor cell mitochondrial respiration, oxidative phosphorylation (OXPHOS), glycolytic reserve, and aspartate biosynthesis. Rescuing aspartate biosynthesis was sufficient to restore proliferation of CD73-deficient tumors in immune-deficient mice. Targeting CD73 decreased metabolic fitness, increased genomic instability, and suppressed PARP activity.","method":"Metabolomics, Seahorse analysis of large panel of mouse and human tumor cell lines, CD73-deficient tumor implantation in immune-deficient mice, aspartate rescue experiments","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — metabolomics plus Seahorse respirometry across multiple cell lines plus in vivo rescue experiment, multiple orthogonal methods","pmids":["37261423"],"is_preprint":false},{"year":2023,"finding":"NT5E/CD73 directly interacts with Aurora kinase A (AURKA) and inhibits AURKA ubiquitination. This interaction, confirmed by co-immunoprecipitation and molecular docking, downregulates p53 signaling and regulates hepatic stellate cell senescence and activation, thereby promoting alcohol-related liver fibrosis.","method":"Co-immunoprecipitation, molecular docking, KEGG pathway analysis, CD73 overexpression/knockdown in stellate cells, proteomic analysis","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifies CD73-AURKA interaction with functional ubiquitination assay, single lab","pmids":["36778123"],"is_preprint":false},{"year":2019,"finding":"CD73 perivascular cell expression (Foxd1+ lineage pericytes/fibroblasts) is required to suppress inflammation and prevent kidney fibrosis after ischemia-reperfusion injury. Conditional deletion of CD73 from perivascular cells increased collagen deposition, proinflammatory markers, and PDGFR-β immunoreactivity. Fibrosis and dysfunction were rescued by administration of soluble CD73 or by macrophage deletion.","method":"Conditional CD73 knockout (Foxd1Cre × CD73fl/fl), unilateral ischemia-reperfusion injury, folic acid nephropathy model, soluble CD73 rescue, macrophage depletion","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with rescue experiment, single lab","pmids":["31364375"],"is_preprint":false},{"year":2013,"finding":"CD73 promotes tumor angiogenesis through both enzymatic (adenosine-dependent) and non-enzymatic functions. Tumor-derived CD73 enhances VEGF production by tumor cells; host-derived CD73 is required for in vivo angiogenic responses; endothelial cells require CD73 expression for tube formation and migration. Anti-CD73 monoclonal antibody treatment significantly decreased tumor VEGF levels and suppressed angiogenesis in vivo.","method":"Mouse breast cancer model with CD73-deficient host cells, in vitro tube formation and migration assays with CD73-knockdown endothelial cells, VEGF ELISA, anti-CD73 antibody treatment","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro loss-of-function with VEGF mechanistic readout, single lab","pmids":["23982901"],"is_preprint":false},{"year":2006,"finding":"Ecto-5'-nucleotidase (CD73) in melanoma cells is catalytically active and is located in lipid rafts. Concanavalin A-induced clustering of CD73 causes its redistribution to heavier cytoskeletal fractions along with co-expressed integrins (αv, α5, β1, β3), caveolin-1, and CD44. Tenascin C inhibits CD73 activity and adenosine generation. Knockdown of CD73 in WM9 cells significantly reduces cell adhesion to tenascin C, indicating a CD73 role in adhesion to extracellular matrix independent of adenosine generation.","method":"Density gradient centrifugation, enzyme activity assays, concanavalin A clustering, siRNA knockdown of CD73, cell adhesion assay on ECM proteins","journal":"Melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional knockdown with adhesion readout plus biochemical fractionation, single lab","pmids":["16718268"],"is_preprint":false},{"year":2022,"finding":"CD73 deficiency on Foxp3+ regulatory T cells impairs their tissue tropism and immunosuppressive function during cardiac healing post-myocardial infarction. CD73-deficient Tregs showed impaired ability to inhibit inflammatory cytokine production in effector T cells. CD73 on Tregs was found to bind to FoxP3- effector T cells directly.","method":"CD73-knockout Treg adoptive transfer, flow cytometry, permanent coronary ligation mouse model, cytokine assays, IL-2/anti-IL-2 complex Treg expansion","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function in defined cell type with functional and phenotypic readouts, single lab","pmids":["35401839"],"is_preprint":false},{"year":2023,"finding":"Hypoxic conditioning increases the frequency of CD73+ CD4+ T cells and promotes HIV latency. CD73 or adenosine receptor blockade facilitates latent HIV reactivation in vitro, mechanistically linking CD73-mediated adenosine signaling to viral quiescence. CD73+ CD4+ T cells harbor a functional HIV reservoir and can reinitiate productive infection ex vivo.","method":"Systems transcriptomics, hypoxic culture, CD73/adenosine receptor blockade, ex vivo HIV reactivation assay, tissue imaging of lymph nodes from HIV-infected individuals","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological blockade with functional latency reactivation readout plus patient tissue validation, single lab","pmids":["37910505"],"is_preprint":false},{"year":2022,"finding":"CD73 expression defines CD73+CD104+ epithelial progenitor cells in the esophagus with enhanced organoid-forming capacity. Knockdown of CD73 decreases organoid formation rate, demonstrating a functional role of CD73 in esophageal epithelial stem cell self-renewal. IL-4 and IL-13 (via STAT6 signaling) deplete the CD73+CD104+ population, which is associated with basal cell hyperplasia in eosinophilic esophagitis.","method":"Fluorescence-activated cell sorting of CD73+CD104+ vs CD73-CD104+ populations, organoid formation assays, RNA interference knockdown of CD73, single-cell RNA sequencing, STAT6 inhibition","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FACS-based functional isolation plus siRNA knockdown with organoid readout, single lab","pmids":["35108658"],"is_preprint":false},{"year":2022,"finding":"CD73 knockdown in pancreatic cancer cells inhibited ERK/STAT3 pathway activation and activated the E-cadherin pathway, leading to inhibition of cell growth, migration, and G1 cell cycle arrest. A CRISPR/Cas9 protein kinase library screen identified Pbk, Fastk, Cdk19, Adck5, Trim28, and Pfkp as potential regulators of CD73.","method":"CRISPR/Cas9 CD73 knockout in human and murine pancreatic cancer cell lines, flow cytometry cell cycle analysis, migration assay, western blotting of ERK/STAT3 and E-cadherin pathways, kinase library CRISPR screen","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with pathway-level mechanistic follow-up and functional readouts, single lab","pmids":["37835536"],"is_preprint":false},{"year":2022,"finding":"CD73 in lung adenocarcinoma cells physically interacts with EGFR (demonstrated by immunoprecipitation) and promotes activation of the AKT/mTOR signaling pathway, driving proliferation, migration, and invasion.","method":"Immunoprecipitation of CD73-EGFR interaction, siRNA knockdown and overexpression of CD73 in A549 cells, western blotting of AKT/mTOR pathway, proliferation, colony formation, wound healing, and Transwell invasion assays","journal":"BioMed research international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP identifying CD73-EGFR interaction, single lab, single method for the key binding claim","pmids":["35813221"],"is_preprint":false},{"year":2019,"finding":"CD73 knockdown in pancreatic ductal adenocarcinoma inhibited cell growth and induced G1 phase arrest via the AKT/ERK/cyclin D signaling pathway. TNFR2 was identified as involved in CD73-induced AKT and ERK signaling pathway activation in PDAC cells.","method":"CD73 knockdown, cell cycle analysis, western blotting of AKT/ERK/cyclin D, TNFR2 inhibition experiments","journal":"Journal of molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, knockdown with pathway analysis but mechanistic link to TNFR2 not fully characterized","pmids":["30927045"],"is_preprint":false},{"year":2021,"finding":"Structure-based design of methylenephosphonic acid CD73 inhibitors exploited key binding interactions of the known inhibitor AMPCP with human CD73, demonstrating that the catalytic site of CD73 can accommodate this class of competitive inhibitors with high potency and selectivity against related ectonucleotidases.","method":"Structure-based drug design using hCD73 crystal structure with AMPCP, in vitro enzymatic inhibition assays, selectivity profiling against related ectonucleotidases, pharmacokinetic analysis","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — structure-based design validated by in vitro enzymatic assay and selectivity profiling, single lab","pmids":["33399453"],"is_preprint":false},{"year":2014,"finding":"CD73 catalytic activity (AMP to adenosine conversion) can be harnessed to instruct supramolecular hydrogelation: CD73 dephosphorylation of AMP precursors triggers self-assembly of nanofibers forming hydrogels, demonstrating that CD73 enzymatic activity can be coupled to materials formation.","method":"Enzymatic supramolecular hydrogelation assay, nanofiber characterization","journal":"Journal of colloid and interface science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single functional demonstration of CD73 catalytic activity in a non-biological context, single lab","pmids":["25524006"],"is_preprint":false},{"year":2022,"finding":"AHR promotes TET2 expression by binding to the TET2 promoter (kynurenine-dependent), and TET2 in turn regulates NT5E promoter methylation status to control CD73 expression on regulatory T cells. Downregulation of the AHR/TET2/NT5E axis in SLE Tregs is associated with reduced CD73 expression and impaired immunosuppressive function.","method":"ChIP assay (AHR binding to TET2 promoter), methylation-specific analysis of NT5E promoter, kynurenine treatment of Tregs and Jurkat T cells, flow cytometry, adenosine receptor pathway analysis","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP identifies AHR binding to TET2 promoter with functional methylation/expression consequences, single lab","pmids":["36314527"],"is_preprint":false}],"current_model":"NT5E/CD73 is a GPI-anchored ecto-5'-nucleotidase that catalyzes the hydrolysis of extracellular AMP to adenosine (the rate-limiting step in extracellular ATP catabolism), with its enzymatic activity regulated by post-translational ubiquitination (via TRIM21 E3 ligase at K133/208/262/321) and by protein trafficking (disease-causing mutations cause ER retention rather than plasma membrane delivery); beyond adenosine production, CD73 has enzyme-independent functions including direct interaction with EGFR and AURKA, costimulatory T cell signaling (requiring p56lck/CD45/TCR but not catalytic activity or GPI anchor), promotion of epithelial integrity via an A1R→CDC42→N-WASP→ARP2/3 cortical actin axis, support of tumor cell mitochondrial respiration and aspartate biosynthesis, and regulation of osteoblast differentiation via A2BAR signaling, while loss-of-function NT5E mutations in humans abolish enzymatic activity and cause arterial and joint calcifications (CALJA disease)."},"narrative":{"mechanistic_narrative":"NT5E (CD73) is a GPI-anchored ecto-5'-nucleotidase that catalyzes hydrolysis of extracellular AMP to adenosine, the rate-limiting step generating extracellular adenosine that signals through adenosine receptors to control inflammation, tissue homeostasis, and tumor biology [PMID:21288095, PMID:22011440]. The catalytically generated adenosine acts in a receptor-subtype-specific manner: via A1R it inhibits spinal nociception and drives a CDC42→N-WASP→ARP2/3 cortical-actin program that maintains epithelial barrier integrity [PMID:22011440, PMID:26642367]; via A2A it mediates apoptotic-cell- and microglia-associated immunosuppression and feed-forward neuroinflammation [PMID:30689733, PMID:28060378]; and via A2B it promotes osteoblast differentiation and tumor-endothelial invasiveness [PMID:21882189, PMID:30926752]. Loss-of-function NT5E mutations abolish enzyme activity and cause arterial and joint calcifications (CALJA), with adenosine treatment reversing the associated alkaline phosphatase elevation and calcification in patient fibroblasts [PMID:21288095]. Disease-causing mutants are mistrafficked into the ER/secretory apparatus rather than reaching the plasma membrane [PMID:24887587], and surface CD73 abundance is further set by TRIM21-mediated ubiquitination at K133/K208/K262/K321, whose loss stabilizes CD73 and amplifies adenosine-driven CD8+ T cell suppression [PMID:36608132]. Beyond adenosine production, CD73 supports tumor cell mitochondrial respiration, OXPHOS, and aspartate biosynthesis needed for proliferation [PMID:37261423], restrains cGAS-STING sensing of tumor DNA damage [PMID:36409930], and exerts enzyme-independent roles as a costimulatory molecule in T cell activation (requiring p56lck/CD45/TCR but neither catalytic activity nor the GPI anchor) and in matrix adhesion [PMID:9113412, PMID:16718268]. CD73 additionally engages partner proteins directly, interacting with EGFR to activate AKT/mTOR signaling and with AURKA to inhibit its ubiquitination and downregulate p53 signaling [PMID:35813221, PMID:36778123].","teleology":[{"year":1997,"claim":"Established that CD73 has signaling functions separable from its enzymatic role, showing it can costimulate T cell activation without catalysis or membrane anchoring.","evidence":"Jurkat T cell transfection with enzymatic-null and GPI-anchorless CD73 constructs plus functional activation assays","pmids":["9113412"],"confidence":"Medium","gaps":["Molecular partner mediating non-enzymatic costimulation not identified","Dependence on p56lck/CD45/TCR defined functionally but not biochemically"]},{"year":2006,"claim":"Defined a CD73 adhesion function in extracellular matrix engagement independent of adenosine, linking it to integrins and lipid-raft organization.","evidence":"Density gradient fractionation, concanavalin A clustering, siRNA knockdown, and adhesion assays on tenascin C in melanoma cells","pmids":["16718268"],"confidence":"Medium","gaps":["Direct CD73-integrin binding not demonstrated","Mechanism of tenascin C inhibition of activity unresolved"]},{"year":2011,"claim":"Identified NT5E as the causal gene for arterial and joint calcification, proving loss of AMP-to-adenosine activity drives ectopic mineralization and is reversible by adenosine.","evidence":"Targeted sequencing, enzyme assays, in vitro calcification, and wild-type rescue in patient fibroblasts across three families","pmids":["21288095"],"confidence":"High","gaps":["Tissue-specific basis of vascular/joint vulnerability not explained","Link between adenosine loss and alkaline phosphatase elevation mechanistically incomplete"]},{"year":2011,"claim":"Demonstrated CD73 is a principal source of extracellular adenosine in nociceptive circuits, acting on A1R to inhibit pain.","evidence":"Fast-scan cyclic voltammetry, histochemistry, and behavioral assays in Pap/Nt5e double-knockout mice","pmids":["22011440"],"confidence":"High","gaps":["Relative contribution of CD73 vs PAP across tissues not fully partitioned"]},{"year":2011,"claim":"Connected CD73-derived adenosine to bone biology, showing it drives osteoblast differentiation specifically through A2B receptor signaling.","evidence":"CD73-knockout mouse bone phenotyping plus MC3T3-E1 overexpression with A2B vs A2A antagonist dissection","pmids":["21882189"],"confidence":"High","gaps":["Downstream transcriptional effectors of A2BAR in osteoblasts not defined"]},{"year":2013,"claim":"Showed CD73 promotes tumor angiogenesis through both adenosine-dependent and enzyme-independent mechanisms involving VEGF.","evidence":"CD73-deficient host mouse tumor models, endothelial knockdown tube/migration assays, VEGF ELISA, and anti-CD73 antibody treatment","pmids":["23982901"],"confidence":"Medium","gaps":["Molecular basis of the non-enzymatic angiogenic function not defined"]},{"year":2014,"claim":"Explained why disease mutations abolish surface activity by showing mutant CD73 is retained intracellularly rather than trafficked to the plasma membrane.","evidence":"Confocal microscopy, subcellular fractionation, and Malachite green activity assay of DsRed-tagged constructs in COS-7 cells","pmids":["24887587"],"confidence":"High","gaps":["Quality-control machinery recognizing mutant CD73 unidentified"]},{"year":2015,"claim":"Defined an A1R→CDC42→N-WASP→ARP2/3 cortical-actin axis through which CD73-derived adenosine maintains epithelial barrier integrity.","evidence":"CD73 knockout mice, pharmacological inhibition, A1R antagonism, and Rho GTPase/ARP2/3 pathway analysis in endometrial epithelium","pmids":["26642367"],"confidence":"High","gaps":["Generality of this axis beyond endometrial epithelium not established"]},{"year":2017,"claim":"Distinguished CD73 from CD39 in resolving inflammation, showing CD73-generated adenosine specifically drives apoptotic-cell suppression of macrophage TNF via A2a.","evidence":"Enzymatic adenosine depletion, A2a inhibition, CD73-knockout macrophages, ectopic A2a/CD73 co-expression, and a peritonitis model","pmids":["28060378"],"confidence":"High","gaps":["Spatial coupling of CD73 and CD39 in tandem nucleotide catabolism not resolved"]},{"year":2019,"claim":"Extended CD73's immunosuppressive role to neuroinflammation, defining a feed-forward A2AR loop in microglia in Parkinson's models.","evidence":"CD73 inactivation in MPTP mice, LPS-stimulated microglia, laser injury, and adenosine replenishment","pmids":["30689733"],"confidence":"Medium","gaps":["Transcriptional basis of CD73/A2AR co-upregulation not defined"]},{"year":2019,"claim":"Localized CD73 function to tissue-specific compartments, showing perivascular CD73 prevents kidney fibrosis and endothelial CD73 drives glioblastoma invasion via A2B.","evidence":"Foxd1Cre conditional knockout with soluble CD73 rescue in kidney injury; CD73-FLK transgenic GBM models with A2B inhibition","pmids":["31364375","30926752"],"confidence":"Medium","gaps":["A2B downstream effectors (e.g., MMP-2 induction) only partly mapped","Cross-tissue generalizability uncertain"]},{"year":2020,"claim":"Revealed regulated trafficking and transcriptional reprogramming of CD73 in NK cells that converts them to suppressive cells via STAT3-driven IL-10.","evidence":"Live-cell imaging of vesicular CD73 transport, 4-1BBL engagement, STAT3 inhibition, and T cell suppression assays","pmids":["31770109"],"confidence":"Medium","gaps":["Trafficking machinery for CD73 exocytosis not identified"]},{"year":2022,"claim":"Identified upstream epigenetic control of NT5E expression through an AHR/TET2 axis controlling promoter methylation in Tregs.","evidence":"ChIP of AHR at the TET2 promoter, NT5E promoter methylation analysis, and kynurenine treatment of Tregs","pmids":["36314527"],"confidence":"Medium","gaps":["Direct demethylation of NT5E by TET2 not shown biochemically"]},{"year":2022,"claim":"Connected CD73 to Treg tissue tropism and direct effector-T-cell binding during cardiac repair, and to epithelial stem cell self-renewal.","evidence":"CD73-knockout Treg adoptive transfer in myocardial infarction; FACS isolation and organoid assays of CD73+CD104+ esophageal progenitors","pmids":["35401839","35108658"],"confidence":"Medium","gaps":["Binding partner mediating Treg-effector contact unidentified","Mechanism of CD73 in stem cell self-renewal undefined"]},{"year":2023,"claim":"Established post-translational control of CD73 stability via TRIM21-mediated ubiquitination, defining the lysine residues and the tumor-immunosuppressive consequence.","evidence":"Co-IP, ubiquitylation assays, site-directed mutagenesis of K133/K208/K262/K321, TRIM21 manipulation, and CD8+ T cell assays","pmids":["36608132"],"confidence":"High","gaps":["Signals controlling TRIM21-CD73 engagement not identified"]},{"year":2023,"claim":"Uncovered enzyme-independent CD73 functions in cancer metabolism and DNA-damage sensing — supporting OXPHOS/aspartate biosynthesis and restraining cGAS-STING.","evidence":"Metabolomics, Seahorse respirometry, aspartate rescue in immune-deficient mice; CRISPR CD73/cGAS deletion in KPC tumor models with AB680","pmids":["37261423","36409930"],"confidence":"High","gaps":["Molecular mechanism coupling CD73 to mitochondrial respiration unresolved","How CD73 loss elevates DNA damage not defined"]},{"year":2023,"claim":"Defined direct protein-protein interactions of CD73 with AURKA, stabilizing AURKA by blocking its ubiquitination and downregulating p53 in liver fibrosis.","evidence":"Co-immunoprecipitation, molecular docking, and CD73 modulation in hepatic stellate cells","pmids":["36778123"],"confidence":"Medium","gaps":["Structural interface of CD73-AURKA not validated experimentally","Mechanism of ubiquitination inhibition unclear"]},{"year":null,"claim":"How CD73's enzyme-independent scaffolding functions (EGFR, AURKA, integrin, costimulatory) are structurally and mechanistically integrated with its canonical catalytic role remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking catalytic and scaffolding functions","EGFR interaction rests on single Co-IP","Determinants of CD73 partner selection unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,4,23,24]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[10,13]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,16]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,6,7,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,7,10,17]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,12]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[10,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1]}],"complexes":[],"partners":["EGFR","AURKA","TRIM21"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21589","full_name":"5'-nucleotidase","aliases":["5'-deoxynucleotidase","Ecto-5'-nucleotidase","IMP-specific 5'-nucleotidase","Thymidylate 5'-phosphatase"],"length_aa":574,"mass_kda":63.4,"function":"Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, with AMP being the preferred substrate (PubMed:21933152, PubMed:22997138, PubMed:23142347, PubMed:24887587, PubMed:34403084). Shows a preference for ribonucleotide monophosphates over their equivalent deoxyribose forms (PubMed:34403084). Other substrates include IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD and NMN (PubMed:21933152, PubMed:22997138, PubMed:23142347, PubMed:24887587, PubMed:34403084)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P21589/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NT5E","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NT5E","total_profiled":1310},"omim":[{"mim_id":"619798","title":"E74-LIKE ETS TRANSCRIPTION FACTOR 2; ELF2","url":"https://www.omim.org/entry/619798"},{"mim_id":"607102","title":"WT1 TRANSCRIPTION FACTOR; WT1","url":"https://www.omim.org/entry/607102"},{"mim_id":"601752","title":"ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; ENTPD1","url":"https://www.omim.org/entry/601752"},{"mim_id":"211800","title":"CALCIFICATION OF JOINTS AND ARTERIES; CALJA","url":"https://www.omim.org/entry/211800"},{"mim_id":"208000","title":"ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1","url":"https://www.omim.org/entry/208000"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"cervix","ntpm":105.8}],"url":"https://www.proteinatlas.org/search/NT5E"},"hgnc":{"alias_symbol":["CD73","eN","eNT","CALJA"],"prev_symbol":["NT5"]},"alphafold":{"accession":"P21589","domains":[{"cath_id":"3.60.21.10","chopping":"28-323","consensus_level":"medium","plddt":97.2965,"start":28,"end":323},{"cath_id":"3.90.780.10","chopping":"338-549","consensus_level":"high","plddt":96.4356,"start":338,"end":549}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21589","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21589-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21589-F1-predicted_aligned_error_v6.png","plddt_mean":91.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NT5E","jax_strain_url":"https://www.jax.org/strain/search?query=NT5E"},"sequence":{"accession":"P21589","fasta_url":"https://rest.uniprot.org/uniprotkb/P21589.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21589/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21589"}},"corpus_meta":[{"pmid":"23601906","id":"PMC_23601906","title":"CD39 and CD73 in immunity and inflammation.","date":"2013","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23601906","citation_count":1013,"is_preprint":false},{"pmid":"21288095","id":"PMC_21288095","title":"NT5E mutations and arterial calcifications.","date":"2011","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21288095","citation_count":382,"is_preprint":false},{"pmid":"36859386","id":"PMC_36859386","title":"CD39/CD73/A2AR pathway and cancer immunotherapy.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36859386","citation_count":298,"is_preprint":false},{"pmid":"9553767","id":"PMC_9553767","title":"Ecto-enzyme and signaling functions of lymphocyte CD73.","date":"1998","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/9553767","citation_count":274,"is_preprint":false},{"pmid":"22396496","id":"PMC_22396496","title":"CD73-deficient mice are resistant to carcinogenesis.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22396496","citation_count":179,"is_preprint":false},{"pmid":"31770109","id":"PMC_31770109","title":"CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31770109","citation_count":173,"is_preprint":false},{"pmid":"25126561","id":"PMC_25126561","title":"The roles of CD73 in cancer.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25126561","citation_count":168,"is_preprint":false},{"pmid":"23982901","id":"PMC_23982901","title":"Anti-CD73 therapy impairs tumor angiogenesis.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23982901","citation_count":148,"is_preprint":false},{"pmid":"26226423","id":"PMC_26226423","title":"CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/26226423","citation_count":146,"is_preprint":false},{"pmid":"23199317","id":"PMC_23199317","title":"CD73 and adenosine generation in the creation of regulatory microenvironments.","date":"2013","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23199317","citation_count":144,"is_preprint":false},{"pmid":"32777746","id":"PMC_32777746","title":"Targeting CD73 to augment cancer immunotherapy.","date":"2020","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32777746","citation_count":137,"is_preprint":false},{"pmid":"28158983","id":"PMC_28158983","title":"CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28158983","citation_count":128,"is_preprint":false},{"pmid":"29758241","id":"PMC_29758241","title":"Targeting the CD73-adenosine axis in immuno-oncology.","date":"2018","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29758241","citation_count":123,"is_preprint":false},{"pmid":"30556751","id":"PMC_30556751","title":"CD73 as a potential opportunity for cancer immunotherapy.","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/30556751","citation_count":122,"is_preprint":false},{"pmid":"32047024","id":"PMC_32047024","title":"CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection.","date":"2020","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32047024","citation_count":116,"is_preprint":false},{"pmid":"31223045","id":"PMC_31223045","title":"CD73: an emerging checkpoint for cancer immunotherapy.","date":"2019","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31223045","citation_count":111,"is_preprint":false},{"pmid":"26808918","id":"PMC_26808918","title":"CD73-adenosine: a next-generation target in immuno-oncology.","date":"2016","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26808918","citation_count":110,"is_preprint":false},{"pmid":"21882189","id":"PMC_21882189","title":"CD73-generated adenosine promotes osteoblast differentiation.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21882189","citation_count":103,"is_preprint":false},{"pmid":"28855210","id":"PMC_28855210","title":"CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28855210","citation_count":103,"is_preprint":false},{"pmid":"17962625","id":"PMC_17962625","title":"VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17962625","citation_count":93,"is_preprint":false},{"pmid":"31461341","id":"PMC_31461341","title":"Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).","date":"2019","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31461341","citation_count":92,"is_preprint":false},{"pmid":"16718268","id":"PMC_16718268","title":"Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma.","date":"2006","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/16718268","citation_count":89,"is_preprint":false},{"pmid":"29720980","id":"PMC_29720980","title":"Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29720980","citation_count":88,"is_preprint":false},{"pmid":"22454080","id":"PMC_22454080","title":"NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.","date":"2012","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22454080","citation_count":83,"is_preprint":false},{"pmid":"27284054","id":"PMC_27284054","title":"The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey.","date":"2016","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/27284054","citation_count":81,"is_preprint":false},{"pmid":"30689733","id":"PMC_30689733","title":"CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.","date":"2019","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30689733","citation_count":80,"is_preprint":false},{"pmid":"26642367","id":"PMC_26642367","title":"Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26642367","citation_count":76,"is_preprint":false},{"pmid":"32351498","id":"PMC_32351498","title":"CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32351498","citation_count":70,"is_preprint":false},{"pmid":"30926752","id":"PMC_30926752","title":"CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30926752","citation_count":69,"is_preprint":false},{"pmid":"31024543","id":"PMC_31024543","title":"Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31024543","citation_count":67,"is_preprint":false},{"pmid":"27563888","id":"PMC_27563888","title":"Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27563888","citation_count":65,"is_preprint":false},{"pmid":"36409930","id":"PMC_36409930","title":"CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.","date":"2023","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36409930","citation_count":59,"is_preprint":false},{"pmid":"28060378","id":"PMC_28060378","title":"CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28060378","citation_count":59,"is_preprint":false},{"pmid":"34116887","id":"PMC_34116887","title":"The elegant complexity of mammalian ecto-5'-nucleotidase (CD73).","date":"2021","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34116887","citation_count":55,"is_preprint":false},{"pmid":"30927045","id":"PMC_30927045","title":"The distinct role of CD73 in the progression of pancreatic cancer.","date":"2019","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30927045","citation_count":53,"is_preprint":false},{"pmid":"31404305","id":"PMC_31404305","title":"Generation and Function of Non-cell-bound CD73 in Inflammation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31404305","citation_count":52,"is_preprint":false},{"pmid":"37511518","id":"PMC_37511518","title":"The Clinical Significance of CD73 in Cancer.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511518","citation_count":52,"is_preprint":false},{"pmid":"9113412","id":"PMC_9113412","title":"T cell signalling through CD73.","date":"1997","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/9113412","citation_count":52,"is_preprint":false},{"pmid":"33430239","id":"PMC_33430239","title":"CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33430239","citation_count":52,"is_preprint":false},{"pmid":"25677906","id":"PMC_25677906","title":"The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25677906","citation_count":50,"is_preprint":false},{"pmid":"35401839","id":"PMC_35401839","title":"CD4+FoxP3+CD73+ regulatory T cell promotes cardiac healing post-myocardial infarction.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35401839","citation_count":49,"is_preprint":false},{"pmid":"22011440","id":"PMC_22011440","title":"PAP and NT5E inhibit nociceptive neurotransmission by rapidly hydrolyzing nucleotides to adenosine.","date":"2011","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/22011440","citation_count":48,"is_preprint":false},{"pmid":"30676071","id":"PMC_30676071","title":"CD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30676071","citation_count":44,"is_preprint":false},{"pmid":"29928476","id":"PMC_29928476","title":"CD73 expression and clinical significance in human metastatic melanoma.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29928476","citation_count":42,"is_preprint":false},{"pmid":"34265363","id":"PMC_34265363","title":"Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34265363","citation_count":42,"is_preprint":false},{"pmid":"27757316","id":"PMC_27757316","title":"Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27757316","citation_count":40,"is_preprint":false},{"pmid":"36720042","id":"PMC_36720042","title":"CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36720042","citation_count":40,"is_preprint":false},{"pmid":"14988475","id":"PMC_14988475","title":"The pea gene LH encodes ent-kaurene oxidase.","date":"2004","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14988475","citation_count":39,"is_preprint":false},{"pmid":"27281619","id":"PMC_27281619","title":"MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27281619","citation_count":38,"is_preprint":false},{"pmid":"38969159","id":"PMC_38969159","title":"Neutrophil extracellular traps promote immune escape in hepatocellular carcinoma by up-regulating CD73 through Notch2.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38969159","citation_count":37,"is_preprint":false},{"pmid":"35711418","id":"PMC_35711418","title":"The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35711418","citation_count":37,"is_preprint":false},{"pmid":"29155108","id":"PMC_29155108","title":"Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/29155108","citation_count":35,"is_preprint":false},{"pmid":"31547570","id":"PMC_31547570","title":"NT5E/CD73 as Correlative Factor of Patient Survival and Natural Killer Cell Infiltration in Glioblastoma.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31547570","citation_count":34,"is_preprint":false},{"pmid":"30607549","id":"PMC_30607549","title":"CD73 expression in normal and pathological human hepatobiliopancreatic tissues.","date":"2019","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/30607549","citation_count":32,"is_preprint":false},{"pmid":"35598361","id":"PMC_35598361","title":"The regulation of CD73 in non-small cell lung cancer.","date":"2022","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/35598361","citation_count":32,"is_preprint":false},{"pmid":"25268760","id":"PMC_25268760","title":"Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25268760","citation_count":31,"is_preprint":false},{"pmid":"33037085","id":"PMC_33037085","title":"PCBP2 Posttranscriptional Modifications Induce Breast Cancer Progression via Upregulation of UFD1 and NT5E.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/33037085","citation_count":30,"is_preprint":false},{"pmid":"35108658","id":"PMC_35108658","title":"CD73+ Epithelial Progenitor Cells That Contribute to Homeostasis and Renewal Are Depleted in Eosinophilic Esophagitis.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35108658","citation_count":29,"is_preprint":false},{"pmid":"31014364","id":"PMC_31014364","title":"Downregulation of CD73 associates with T cell exhaustion in AML patients.","date":"2019","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31014364","citation_count":29,"is_preprint":false},{"pmid":"36608132","id":"PMC_36608132","title":"Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36608132","citation_count":28,"is_preprint":false},{"pmid":"33086655","id":"PMC_33086655","title":"CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33086655","citation_count":28,"is_preprint":false},{"pmid":"33399453","id":"PMC_33399453","title":"Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33399453","citation_count":28,"is_preprint":false},{"pmid":"26629888","id":"PMC_26629888","title":"A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity.","date":"2015","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/26629888","citation_count":27,"is_preprint":false},{"pmid":"26178434","id":"PMC_26178434","title":"Calcification of joints and arteries: second report with novel NT5E mutations and expansion of the phenotype.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26178434","citation_count":26,"is_preprint":false},{"pmid":"38652041","id":"PMC_38652041","title":"Regulatory role of CD39 and CD73 in tumor immunity.","date":"2024","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38652041","citation_count":26,"is_preprint":false},{"pmid":"36165836","id":"PMC_36165836","title":"Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.","date":"2022","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/36165836","citation_count":26,"is_preprint":false},{"pmid":"31364375","id":"PMC_31364375","title":"Perivascular CD73+ cells attenuate inflammation and interstitial fibrosis in the kidney microenvironment.","date":"2019","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31364375","citation_count":25,"is_preprint":false},{"pmid":"31927318","id":"PMC_31927318","title":"ent-Labdane and ent-kaurane diterpenoids from Chelonopsis odontochila with α-glucosidase inhibitory activity.","date":"2020","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31927318","citation_count":23,"is_preprint":false},{"pmid":"37033953","id":"PMC_37033953","title":"Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37033953","citation_count":22,"is_preprint":false},{"pmid":"31812109","id":"PMC_31812109","title":"Ent-abietane and ent-pimarane diterpenoids from Croton mubango (Euphorbiaceae).","date":"2019","source":"Phytochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31812109","citation_count":21,"is_preprint":false},{"pmid":"33416944","id":"PMC_33416944","title":"CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/33416944","citation_count":21,"is_preprint":false},{"pmid":"31652269","id":"PMC_31652269","title":"Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31652269","citation_count":21,"is_preprint":false},{"pmid":"30417547","id":"PMC_30417547","title":"Ecto-5'-nucleotidase (CD73) is a potential target of hepatocellular carcinoma.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30417547","citation_count":21,"is_preprint":false},{"pmid":"37327456","id":"PMC_37327456","title":"Combining High-Z Sensitized Radiotherapy with CD73 Blockade to Boost Tumor Immunotherapy.","date":"2023","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/37327456","citation_count":21,"is_preprint":false},{"pmid":"30184475","id":"PMC_30184475","title":"Activity of ecto-5'-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30184475","citation_count":20,"is_preprint":false},{"pmid":"35813221","id":"PMC_35813221","title":"CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/35813221","citation_count":19,"is_preprint":false},{"pmid":"27649126","id":"PMC_27649126","title":"ent-Pimarane and ent-Kaurane Diterpenes from Aldama discolor (Asteraceae) and Their Antiprotozoal Activity.","date":"2016","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/27649126","citation_count":18,"is_preprint":false},{"pmid":"30155470","id":"PMC_30155470","title":"Extracellular ATP Regulates CD73 and ABCC6 Expression in HepG2 Cells.","date":"2018","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30155470","citation_count":18,"is_preprint":false},{"pmid":"39090604","id":"PMC_39090604","title":"Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39090604","citation_count":17,"is_preprint":false},{"pmid":"36314527","id":"PMC_36314527","title":"AHR/TET2/NT5E axis downregulation is associated with the risk of systemic lupus erythematosus and its progression.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36314527","citation_count":17,"is_preprint":false},{"pmid":"37910505","id":"PMC_37910505","title":"The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37910505","citation_count":17,"is_preprint":false},{"pmid":"39285178","id":"PMC_39285178","title":"Blockade of CD73 potentiates radiotherapy antitumor immunity and abscopal effects via STING pathway.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39285178","citation_count":16,"is_preprint":false},{"pmid":"36778123","id":"PMC_36778123","title":"CD73/NT5E-mediated ubiquitination of AURKA regulates alcohol-related liver fibrosis via modulating hepatic stellate cell senescence.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36778123","citation_count":16,"is_preprint":false},{"pmid":"37261423","id":"PMC_37261423","title":"The CD73 immune checkpoint promotes tumor cell metabolic fitness.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37261423","citation_count":16,"is_preprint":false},{"pmid":"35622118","id":"PMC_35622118","title":"Functional expression of CD73 on human natural killer cells.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/35622118","citation_count":16,"is_preprint":false},{"pmid":"34310891","id":"PMC_34310891","title":"Transcriptome Profiling Reveals CD73 and Age-Driven Changes in Neutrophil Responses against Streptococcus pneumoniae.","date":"2021","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/34310891","citation_count":16,"is_preprint":false},{"pmid":"41188606","id":"PMC_41188606","title":"CD39 and CD73: biological functions, diseases and therapy.","date":"2025","source":"Molecular biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/41188606","citation_count":15,"is_preprint":false},{"pmid":"29943212","id":"PMC_29943212","title":"En route into chloroplasts: preproteins' way home.","date":"2018","source":"Photosynthesis research","url":"https://pubmed.ncbi.nlm.nih.gov/29943212","citation_count":15,"is_preprint":false},{"pmid":"35163489","id":"PMC_35163489","title":"CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163489","citation_count":15,"is_preprint":false},{"pmid":"33745072","id":"PMC_33745072","title":"Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth.","date":"2021","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/33745072","citation_count":15,"is_preprint":false},{"pmid":"16519912","id":"PMC_16519912","title":"Synthesis of ent-25-hydroxycholesterol.","date":"2006","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/16519912","citation_count":15,"is_preprint":false},{"pmid":"37620936","id":"PMC_37620936","title":"5'-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells.","date":"2023","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/37620936","citation_count":14,"is_preprint":false},{"pmid":"9638974","id":"PMC_9638974","title":"CD73 and adhesion of B-cells to follicular dendritic cells.","date":"1998","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9638974","citation_count":14,"is_preprint":false},{"pmid":"35620732","id":"PMC_35620732","title":"The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35620732","citation_count":13,"is_preprint":false},{"pmid":"37835536","id":"PMC_37835536","title":"Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37835536","citation_count":13,"is_preprint":false},{"pmid":"32067282","id":"PMC_32067282","title":"MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32067282","citation_count":12,"is_preprint":false},{"pmid":"24887587","id":"PMC_24887587","title":"NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24887587","citation_count":12,"is_preprint":false},{"pmid":"28218684","id":"PMC_28218684","title":"Ent-Abietanoids Isolated from Isodon serra.","date":"2017","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28218684","citation_count":12,"is_preprint":false},{"pmid":"38086190","id":"PMC_38086190","title":"Small molecular CD73 inhibitors: Recent progress and future perspectives.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38086190","citation_count":11,"is_preprint":false},{"pmid":"25524006","id":"PMC_25524006","title":"The first CD73-instructed supramolecular hydrogel.","date":"2014","source":"Journal of colloid and interface science","url":"https://pubmed.ncbi.nlm.nih.gov/25524006","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47257,"output_tokens":7008,"usd":0.123445,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16403,"output_tokens":5036,"usd":0.103957,"stage2_stop_reason":"end_turn"},"total_usd":0.227402,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"NT5E/CD73 converts AMP to adenosine; loss-of-function mutations (nonsense p.S221X, missense p.C358Y, frameshift p.V537fsX7) abolish this enzyme activity and cause arterial and joint calcifications. Cultured fibroblasts from affected patients showed markedly reduced CD73 protein, absent enzyme activity, elevated alkaline phosphatase, and accumulated calcium phosphate crystals. Genetic rescue with wild-type NT5E normalized CD73 and alkaline phosphatase activity; adenosine treatment reduced alkaline phosphatase levels and calcification.\",\n      \"method\": \"Western blotting, enzyme activity assays, in vitro calcification assays, transduction rescue experiments, SNP analysis, targeted gene sequencing\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (enzyme assay, rescue experiment, in vitro calcification), replicated across three independent families\",\n      \"pmids\": [\"21288095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Disease-causing NT5E mutations (p.S221X, p.C358Y, p.V537fsX7) result in mistrafficking of NT5E protein away from the plasma membrane: mutant proteins accumulate in the cell synthetic apparatus (ER/vesicles) rather than reaching the cell surface, with reduced ER retention and absent NT5E enzymatic activity at the cell surface.\",\n      \"method\": \"Confocal microscopy, western blot of fractionated cell constituents, enzyme histochemistry (Malachite green assay), heterologous expression of DsRed-tagged wild-type and mutant NT5E in COS-7 cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (subcellular fractionation, confocal imaging, enzymatic assay) in a single focused study\",\n      \"pmids\": [\"24887587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CD73 functions as a costimulatory molecule for T cell activation independently of its enzymatic activity and independently of its GPI anchor (demonstrated using a Jurkat T cell transfection model); however, expression of p56lck, CD45, and the T cell receptor are required for CD73-mediated T cell activation in vitro.\",\n      \"method\": \"Jurkat T cell transfection with CD73 cDNA constructs (enzymatic-activity-null and GPI-anchorless mutants), functional T cell activation assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined genetic dissection of enzymatic vs. non-enzymatic function with multiple constructs, single lab\",\n      \"pmids\": [\"9113412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CD73-generated adenosine promotes osteoblast differentiation via A2B adenosine receptor (A2BAR) signaling. CD73-deficient mice show osteopenia with reduced osteoblastic markers but normal osteoclastic markers. Overexpression of CD73 in MC3T3-E1 cells enhanced osteocalcin and bone sialoprotein expression, an effect blocked by an A2BAR antagonist but not an A2AAR antagonist.\",\n      \"method\": \"CD73-knockout mouse bone phenotyping, in vitro osteoblast differentiation assays, CD73 overexpression in MC3T3-E1 cells, pharmacological receptor antagonism\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout phenotype corroborated by in vitro gain-of-function and pharmacological dissection of receptor subtype, multiple orthogonal approaches\",\n      \"pmids\": [\"21882189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NT5E (CD73) and PAP are the principal ectonucleotidases generating adenosine in spinal nociceptive circuits. AMP hydrolysis was nearly abolished in dorsal root ganglia and spinal cord lamina II of Pap/Nt5e double-knockout mice. NT5E rapidly converts AMP to adenosine within seconds in lamina II (measured by fast-scan cyclic voltammetry), and the resulting adenosine inhibits nociception via the A1 adenosine receptor.\",\n      \"method\": \"Histochemical AMP hydrolysis, fast-scan cyclic voltammetry in spinal lamina II, behavioral nociception assays, Pap/Nt5e double-knockout mice, pharmacological A1 receptor analysis\",\n      \"journal\": \"Molecular pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo knockout combined with real-time electrochemical adenosine measurement and behavioral/electrophysiological readouts, multiple orthogonal methods\",\n      \"pmids\": [\"22011440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD73-generated adenosine induces cortical actin polymerization in endometrial epithelial cells via adenosine A1 receptor (A1R) activation of a Rho GTPase CDC42-dependent conformational change of the N-WASP subunit of the ARP2/3 complex. This cortical F-actin elevation increases membrane E-cadherin, β-catenin, and Na+K+ ATPase, maintaining epithelial integrity. Loss of CD73 reduces endometrial epithelial barrier function and increases migration/invasion.\",\n      \"method\": \"CD73 pharmacological inhibition, CD73 knockout mouse model, in vitro migration/invasion assays, co-localization of CD73 with cell-cell contacts and filopodia, A1R antagonism, Rho GTPase and ARP2/3 pathway analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway dissection with multiple orthogonal approaches (KO mice, pharmacological inhibition, pathway-specific inhibitors), defining A1R→CDC42→N-WASP→ARP2/3 axis\",\n      \"pmids\": [\"26642367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD73-derived adenosine activates adenosine A2A receptor (A2AR) in a feed-forward manner in microglia, upregulating CD73 and A2AR to promote neuroinflammation in Parkinson's disease models. CD73 inactivation attenuated LPS-induced pro-inflammatory responses, enhanced microglial process extension and movement, and suppressed microglia-mediated neuroinflammation. A2AR-mediated pro-inflammation was restored by exogenous adenosine analogues.\",\n      \"method\": \"CD73 inactivation in MPTP mouse model, LPS-stimulated microglia assays, laser injury model, pharmacological adenosine replenishment, morphological analysis of microglia\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro loss-of-function with mechanistic rescue, single lab\",\n      \"pmids\": [\"30689733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned macrophages. Adenosine generated by CD73 (AMP→adenosine) but not CD39 (ATP→AMP) is required for apoptotic cell-driven suppression of TNF in LPS-conditioned macrophages, acting through the adenosine A2a receptor (Adora2a). In mice, CD73 was required to limit neutrophil influx in a peritonitis model.\",\n      \"method\": \"Enzymatic depletion of adenosine, pharmacological A2a receptor inhibition, CD73-knockout macrophages, RAW264.7 ectopic co-expression of A2a and CD73, in vivo peritonitis model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus pharmacological inhibition plus ectopic expression rescue, multiple orthogonal approaches dissecting CD73-specific (not CD39) requirement\",\n      \"pmids\": [\"28060378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tumor-infiltrating NK cells transport CD73 in intracellular vesicles to the cell surface and extracellular space via actin polymerization-dependent exocytosis, triggered by engagement of 4-1BBL on tumor cells. CD73-positive NK cells undergo transcriptional reprogramming with upregulated IL-10 production via STAT3 transcriptional activity, suppressing CD4+ T cell proliferation and IFN-γ production.\",\n      \"method\": \"Flow cytometry, live cell imaging of CD73-vesicle trafficking, cytokine assays, STAT3 inhibition, functional T cell suppression assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection of vesicle transport and STAT3-IL-10 axis, single lab with multiple methods\",\n      \"pmids\": [\"31770109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD73 on glioblastoma endothelial cells promotes tumor invasiveness through A2B adenosine receptor (A2B AR) signaling, which induces matrix metalloproteinase-2 (MMP-2) expression. Inhibition of A2B AR signaling decreased multidrug resistance transporter expression (P-gp and MRP1) and potentiated temozolomide-induced cell death. The CD73-FLK mouse model demonstrated that endothelial CD73 drives tumor invasiveness and brain morphology distortion.\",\n      \"method\": \"CD73-knockout and CD73-FLK transgenic mouse GBM models, A2B AR inhibition, immunohistochemistry, tumor growth/vessel density measurement\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — spatially-defined genetic models and pharmacological intervention, single lab\",\n      \"pmids\": [\"30926752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM21 is an E3 ubiquitin ligase that targets CD73 for ubiquitin-mediated proteolytic degradation. Lysine residues K133, K208, K262, and K321 on CD73 are required for TRIM21-mediated ubiquitylation and degradation. Loss of TRIM21 stabilizes CD73, enhancing CD73-catalyzed adenosine production and suppressing CD8+ T cell function, promoting tumor growth.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitylation assays, site-directed mutagenesis of CD73 lysine residues, TRIM21 knockout/overexpression, CD8+ T cell functional assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct biochemical identification of E3 ligase (Co-IP), mutagenesis of ubiquitylation sites, functional cellular consequences, multiple orthogonal methods\",\n      \"pmids\": [\"36608132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CD73 deficiency in pancreatic tumor cells leads to increased DNA damage and activation of the cGAS-STING pathway. cGAS expression in tumor cells was required for the antitumor activity of the CD73 inhibitor AB680 in vivo, linking CD73 to suppression of innate immune sensing of tumor DNA damage.\",\n      \"method\": \"CRISPR/genetic CD73 deletion in mouse KPC tumor cells, cGAS knockout, in vivo tumor models, pharmacogenomic analysis of human PDAC cell lines\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo (cGAS required for CD73 inhibitor effect), complemented by pharmacogenomics, single lab\",\n      \"pmids\": [\"36409930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CD73 significantly enhances tumor cell mitochondrial respiration, oxidative phosphorylation (OXPHOS), glycolytic reserve, and aspartate biosynthesis. Rescuing aspartate biosynthesis was sufficient to restore proliferation of CD73-deficient tumors in immune-deficient mice. Targeting CD73 decreased metabolic fitness, increased genomic instability, and suppressed PARP activity.\",\n      \"method\": \"Metabolomics, Seahorse analysis of large panel of mouse and human tumor cell lines, CD73-deficient tumor implantation in immune-deficient mice, aspartate rescue experiments\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — metabolomics plus Seahorse respirometry across multiple cell lines plus in vivo rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"37261423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NT5E/CD73 directly interacts with Aurora kinase A (AURKA) and inhibits AURKA ubiquitination. This interaction, confirmed by co-immunoprecipitation and molecular docking, downregulates p53 signaling and regulates hepatic stellate cell senescence and activation, thereby promoting alcohol-related liver fibrosis.\",\n      \"method\": \"Co-immunoprecipitation, molecular docking, KEGG pathway analysis, CD73 overexpression/knockdown in stellate cells, proteomic analysis\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifies CD73-AURKA interaction with functional ubiquitination assay, single lab\",\n      \"pmids\": [\"36778123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD73 perivascular cell expression (Foxd1+ lineage pericytes/fibroblasts) is required to suppress inflammation and prevent kidney fibrosis after ischemia-reperfusion injury. Conditional deletion of CD73 from perivascular cells increased collagen deposition, proinflammatory markers, and PDGFR-β immunoreactivity. Fibrosis and dysfunction were rescued by administration of soluble CD73 or by macrophage deletion.\",\n      \"method\": \"Conditional CD73 knockout (Foxd1Cre × CD73fl/fl), unilateral ischemia-reperfusion injury, folic acid nephropathy model, soluble CD73 rescue, macrophage depletion\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with rescue experiment, single lab\",\n      \"pmids\": [\"31364375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD73 promotes tumor angiogenesis through both enzymatic (adenosine-dependent) and non-enzymatic functions. Tumor-derived CD73 enhances VEGF production by tumor cells; host-derived CD73 is required for in vivo angiogenic responses; endothelial cells require CD73 expression for tube formation and migration. Anti-CD73 monoclonal antibody treatment significantly decreased tumor VEGF levels and suppressed angiogenesis in vivo.\",\n      \"method\": \"Mouse breast cancer model with CD73-deficient host cells, in vitro tube formation and migration assays with CD73-knockdown endothelial cells, VEGF ELISA, anti-CD73 antibody treatment\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro loss-of-function with VEGF mechanistic readout, single lab\",\n      \"pmids\": [\"23982901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ecto-5'-nucleotidase (CD73) in melanoma cells is catalytically active and is located in lipid rafts. Concanavalin A-induced clustering of CD73 causes its redistribution to heavier cytoskeletal fractions along with co-expressed integrins (αv, α5, β1, β3), caveolin-1, and CD44. Tenascin C inhibits CD73 activity and adenosine generation. Knockdown of CD73 in WM9 cells significantly reduces cell adhesion to tenascin C, indicating a CD73 role in adhesion to extracellular matrix independent of adenosine generation.\",\n      \"method\": \"Density gradient centrifugation, enzyme activity assays, concanavalin A clustering, siRNA knockdown of CD73, cell adhesion assay on ECM proteins\",\n      \"journal\": \"Melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional knockdown with adhesion readout plus biochemical fractionation, single lab\",\n      \"pmids\": [\"16718268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD73 deficiency on Foxp3+ regulatory T cells impairs their tissue tropism and immunosuppressive function during cardiac healing post-myocardial infarction. CD73-deficient Tregs showed impaired ability to inhibit inflammatory cytokine production in effector T cells. CD73 on Tregs was found to bind to FoxP3- effector T cells directly.\",\n      \"method\": \"CD73-knockout Treg adoptive transfer, flow cytometry, permanent coronary ligation mouse model, cytokine assays, IL-2/anti-IL-2 complex Treg expansion\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function in defined cell type with functional and phenotypic readouts, single lab\",\n      \"pmids\": [\"35401839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hypoxic conditioning increases the frequency of CD73+ CD4+ T cells and promotes HIV latency. CD73 or adenosine receptor blockade facilitates latent HIV reactivation in vitro, mechanistically linking CD73-mediated adenosine signaling to viral quiescence. CD73+ CD4+ T cells harbor a functional HIV reservoir and can reinitiate productive infection ex vivo.\",\n      \"method\": \"Systems transcriptomics, hypoxic culture, CD73/adenosine receptor blockade, ex vivo HIV reactivation assay, tissue imaging of lymph nodes from HIV-infected individuals\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological blockade with functional latency reactivation readout plus patient tissue validation, single lab\",\n      \"pmids\": [\"37910505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD73 expression defines CD73+CD104+ epithelial progenitor cells in the esophagus with enhanced organoid-forming capacity. Knockdown of CD73 decreases organoid formation rate, demonstrating a functional role of CD73 in esophageal epithelial stem cell self-renewal. IL-4 and IL-13 (via STAT6 signaling) deplete the CD73+CD104+ population, which is associated with basal cell hyperplasia in eosinophilic esophagitis.\",\n      \"method\": \"Fluorescence-activated cell sorting of CD73+CD104+ vs CD73-CD104+ populations, organoid formation assays, RNA interference knockdown of CD73, single-cell RNA sequencing, STAT6 inhibition\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FACS-based functional isolation plus siRNA knockdown with organoid readout, single lab\",\n      \"pmids\": [\"35108658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD73 knockdown in pancreatic cancer cells inhibited ERK/STAT3 pathway activation and activated the E-cadherin pathway, leading to inhibition of cell growth, migration, and G1 cell cycle arrest. A CRISPR/Cas9 protein kinase library screen identified Pbk, Fastk, Cdk19, Adck5, Trim28, and Pfkp as potential regulators of CD73.\",\n      \"method\": \"CRISPR/Cas9 CD73 knockout in human and murine pancreatic cancer cell lines, flow cytometry cell cycle analysis, migration assay, western blotting of ERK/STAT3 and E-cadherin pathways, kinase library CRISPR screen\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with pathway-level mechanistic follow-up and functional readouts, single lab\",\n      \"pmids\": [\"37835536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD73 in lung adenocarcinoma cells physically interacts with EGFR (demonstrated by immunoprecipitation) and promotes activation of the AKT/mTOR signaling pathway, driving proliferation, migration, and invasion.\",\n      \"method\": \"Immunoprecipitation of CD73-EGFR interaction, siRNA knockdown and overexpression of CD73 in A549 cells, western blotting of AKT/mTOR pathway, proliferation, colony formation, wound healing, and Transwell invasion assays\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP identifying CD73-EGFR interaction, single lab, single method for the key binding claim\",\n      \"pmids\": [\"35813221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD73 knockdown in pancreatic ductal adenocarcinoma inhibited cell growth and induced G1 phase arrest via the AKT/ERK/cyclin D signaling pathway. TNFR2 was identified as involved in CD73-induced AKT and ERK signaling pathway activation in PDAC cells.\",\n      \"method\": \"CD73 knockdown, cell cycle analysis, western blotting of AKT/ERK/cyclin D, TNFR2 inhibition experiments\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, knockdown with pathway analysis but mechanistic link to TNFR2 not fully characterized\",\n      \"pmids\": [\"30927045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Structure-based design of methylenephosphonic acid CD73 inhibitors exploited key binding interactions of the known inhibitor AMPCP with human CD73, demonstrating that the catalytic site of CD73 can accommodate this class of competitive inhibitors with high potency and selectivity against related ectonucleotidases.\",\n      \"method\": \"Structure-based drug design using hCD73 crystal structure with AMPCP, in vitro enzymatic inhibition assays, selectivity profiling against related ectonucleotidases, pharmacokinetic analysis\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-based design validated by in vitro enzymatic assay and selectivity profiling, single lab\",\n      \"pmids\": [\"33399453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD73 catalytic activity (AMP to adenosine conversion) can be harnessed to instruct supramolecular hydrogelation: CD73 dephosphorylation of AMP precursors triggers self-assembly of nanofibers forming hydrogels, demonstrating that CD73 enzymatic activity can be coupled to materials formation.\",\n      \"method\": \"Enzymatic supramolecular hydrogelation assay, nanofiber characterization\",\n      \"journal\": \"Journal of colloid and interface science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single functional demonstration of CD73 catalytic activity in a non-biological context, single lab\",\n      \"pmids\": [\"25524006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"AHR promotes TET2 expression by binding to the TET2 promoter (kynurenine-dependent), and TET2 in turn regulates NT5E promoter methylation status to control CD73 expression on regulatory T cells. Downregulation of the AHR/TET2/NT5E axis in SLE Tregs is associated with reduced CD73 expression and impaired immunosuppressive function.\",\n      \"method\": \"ChIP assay (AHR binding to TET2 promoter), methylation-specific analysis of NT5E promoter, kynurenine treatment of Tregs and Jurkat T cells, flow cytometry, adenosine receptor pathway analysis\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP identifies AHR binding to TET2 promoter with functional methylation/expression consequences, single lab\",\n      \"pmids\": [\"36314527\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NT5E/CD73 is a GPI-anchored ecto-5'-nucleotidase that catalyzes the hydrolysis of extracellular AMP to adenosine (the rate-limiting step in extracellular ATP catabolism), with its enzymatic activity regulated by post-translational ubiquitination (via TRIM21 E3 ligase at K133/208/262/321) and by protein trafficking (disease-causing mutations cause ER retention rather than plasma membrane delivery); beyond adenosine production, CD73 has enzyme-independent functions including direct interaction with EGFR and AURKA, costimulatory T cell signaling (requiring p56lck/CD45/TCR but not catalytic activity or GPI anchor), promotion of epithelial integrity via an A1R→CDC42→N-WASP→ARP2/3 cortical actin axis, support of tumor cell mitochondrial respiration and aspartate biosynthesis, and regulation of osteoblast differentiation via A2BAR signaling, while loss-of-function NT5E mutations in humans abolish enzymatic activity and cause arterial and joint calcifications (CALJA disease).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NT5E (CD73) is a GPI-anchored ecto-5'-nucleotidase that catalyzes hydrolysis of extracellular AMP to adenosine, the rate-limiting step generating extracellular adenosine that signals through adenosine receptors to control inflammation, tissue homeostasis, and tumor biology [#0, #4]. The catalytically generated adenosine acts in a receptor-subtype-specific manner: via A1R it inhibits spinal nociception and drives a CDC42→N-WASP→ARP2/3 cortical-actin program that maintains epithelial barrier integrity [#4, #5]; via A2A it mediates apoptotic-cell- and microglia-associated immunosuppression and feed-forward neuroinflammation [#6, #7]; and via A2B it promotes osteoblast differentiation and tumor-endothelial invasiveness [#3, #9]. Loss-of-function NT5E mutations abolish enzyme activity and cause arterial and joint calcifications (CALJA), with adenosine treatment reversing the associated alkaline phosphatase elevation and calcification in patient fibroblasts [#0]. Disease-causing mutants are mistrafficked into the ER/secretory apparatus rather than reaching the plasma membrane [#1], and surface CD73 abundance is further set by TRIM21-mediated ubiquitination at K133/K208/K262/K321, whose loss stabilizes CD73 and amplifies adenosine-driven CD8+ T cell suppression [#10]. Beyond adenosine production, CD73 supports tumor cell mitochondrial respiration, OXPHOS, and aspartate biosynthesis needed for proliferation [#12], restrains cGAS-STING sensing of tumor DNA damage [#11], and exerts enzyme-independent roles as a costimulatory molecule in T cell activation (requiring p56lck/CD45/TCR but neither catalytic activity nor the GPI anchor) and in matrix adhesion [#2, #16]. CD73 additionally engages partner proteins directly, interacting with EGFR to activate AKT/mTOR signaling and with AURKA to inhibit its ubiquitination and downregulate p53 signaling [#21, #13].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that CD73 has signaling functions separable from its enzymatic role, showing it can costimulate T cell activation without catalysis or membrane anchoring.\",\n      \"evidence\": \"Jurkat T cell transfection with enzymatic-null and GPI-anchorless CD73 constructs plus functional activation assays\",\n      \"pmids\": [\"9113412\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular partner mediating non-enzymatic costimulation not identified\", \"Dependence on p56lck/CD45/TCR defined functionally but not biochemically\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined a CD73 adhesion function in extracellular matrix engagement independent of adenosine, linking it to integrins and lipid-raft organization.\",\n      \"evidence\": \"Density gradient fractionation, concanavalin A clustering, siRNA knockdown, and adhesion assays on tenascin C in melanoma cells\",\n      \"pmids\": [\"16718268\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CD73-integrin binding not demonstrated\", \"Mechanism of tenascin C inhibition of activity unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified NT5E as the causal gene for arterial and joint calcification, proving loss of AMP-to-adenosine activity drives ectopic mineralization and is reversible by adenosine.\",\n      \"evidence\": \"Targeted sequencing, enzyme assays, in vitro calcification, and wild-type rescue in patient fibroblasts across three families\",\n      \"pmids\": [\"21288095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific basis of vascular/joint vulnerability not explained\", \"Link between adenosine loss and alkaline phosphatase elevation mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated CD73 is a principal source of extracellular adenosine in nociceptive circuits, acting on A1R to inhibit pain.\",\n      \"evidence\": \"Fast-scan cyclic voltammetry, histochemistry, and behavioral assays in Pap/Nt5e double-knockout mice\",\n      \"pmids\": [\"22011440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CD73 vs PAP across tissues not fully partitioned\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected CD73-derived adenosine to bone biology, showing it drives osteoblast differentiation specifically through A2B receptor signaling.\",\n      \"evidence\": \"CD73-knockout mouse bone phenotyping plus MC3T3-E1 overexpression with A2B vs A2A antagonist dissection\",\n      \"pmids\": [\"21882189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional effectors of A2BAR in osteoblasts not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed CD73 promotes tumor angiogenesis through both adenosine-dependent and enzyme-independent mechanisms involving VEGF.\",\n      \"evidence\": \"CD73-deficient host mouse tumor models, endothelial knockdown tube/migration assays, VEGF ELISA, and anti-CD73 antibody treatment\",\n      \"pmids\": [\"23982901\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the non-enzymatic angiogenic function not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Explained why disease mutations abolish surface activity by showing mutant CD73 is retained intracellularly rather than trafficked to the plasma membrane.\",\n      \"evidence\": \"Confocal microscopy, subcellular fractionation, and Malachite green activity assay of DsRed-tagged constructs in COS-7 cells\",\n      \"pmids\": [\"24887587\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quality-control machinery recognizing mutant CD73 unidentified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined an A1R→CDC42→N-WASP→ARP2/3 cortical-actin axis through which CD73-derived adenosine maintains epithelial barrier integrity.\",\n      \"evidence\": \"CD73 knockout mice, pharmacological inhibition, A1R antagonism, and Rho GTPase/ARP2/3 pathway analysis in endometrial epithelium\",\n      \"pmids\": [\"26642367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of this axis beyond endometrial epithelium not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Distinguished CD73 from CD39 in resolving inflammation, showing CD73-generated adenosine specifically drives apoptotic-cell suppression of macrophage TNF via A2a.\",\n      \"evidence\": \"Enzymatic adenosine depletion, A2a inhibition, CD73-knockout macrophages, ectopic A2a/CD73 co-expression, and a peritonitis model\",\n      \"pmids\": [\"28060378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial coupling of CD73 and CD39 in tandem nucleotide catabolism not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended CD73's immunosuppressive role to neuroinflammation, defining a feed-forward A2AR loop in microglia in Parkinson's models.\",\n      \"evidence\": \"CD73 inactivation in MPTP mice, LPS-stimulated microglia, laser injury, and adenosine replenishment\",\n      \"pmids\": [\"30689733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional basis of CD73/A2AR co-upregulation not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Localized CD73 function to tissue-specific compartments, showing perivascular CD73 prevents kidney fibrosis and endothelial CD73 drives glioblastoma invasion via A2B.\",\n      \"evidence\": \"Foxd1Cre conditional knockout with soluble CD73 rescue in kidney injury; CD73-FLK transgenic GBM models with A2B inhibition\",\n      \"pmids\": [\"31364375\", \"30926752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"A2B downstream effectors (e.g., MMP-2 induction) only partly mapped\", \"Cross-tissue generalizability uncertain\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed regulated trafficking and transcriptional reprogramming of CD73 in NK cells that converts them to suppressive cells via STAT3-driven IL-10.\",\n      \"evidence\": \"Live-cell imaging of vesicular CD73 transport, 4-1BBL engagement, STAT3 inhibition, and T cell suppression assays\",\n      \"pmids\": [\"31770109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trafficking machinery for CD73 exocytosis not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified upstream epigenetic control of NT5E expression through an AHR/TET2 axis controlling promoter methylation in Tregs.\",\n      \"evidence\": \"ChIP of AHR at the TET2 promoter, NT5E promoter methylation analysis, and kynurenine treatment of Tregs\",\n      \"pmids\": [\"36314527\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demethylation of NT5E by TET2 not shown biochemically\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected CD73 to Treg tissue tropism and direct effector-T-cell binding during cardiac repair, and to epithelial stem cell self-renewal.\",\n      \"evidence\": \"CD73-knockout Treg adoptive transfer in myocardial infarction; FACS isolation and organoid assays of CD73+CD104+ esophageal progenitors\",\n      \"pmids\": [\"35401839\", \"35108658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding partner mediating Treg-effector contact unidentified\", \"Mechanism of CD73 in stem cell self-renewal undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established post-translational control of CD73 stability via TRIM21-mediated ubiquitination, defining the lysine residues and the tumor-immunosuppressive consequence.\",\n      \"evidence\": \"Co-IP, ubiquitylation assays, site-directed mutagenesis of K133/K208/K262/K321, TRIM21 manipulation, and CD8+ T cell assays\",\n      \"pmids\": [\"36608132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling TRIM21-CD73 engagement not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Uncovered enzyme-independent CD73 functions in cancer metabolism and DNA-damage sensing — supporting OXPHOS/aspartate biosynthesis and restraining cGAS-STING.\",\n      \"evidence\": \"Metabolomics, Seahorse respirometry, aspartate rescue in immune-deficient mice; CRISPR CD73/cGAS deletion in KPC tumor models with AB680\",\n      \"pmids\": [\"37261423\", \"36409930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism coupling CD73 to mitochondrial respiration unresolved\", \"How CD73 loss elevates DNA damage not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined direct protein-protein interactions of CD73 with AURKA, stabilizing AURKA by blocking its ubiquitination and downregulating p53 in liver fibrosis.\",\n      \"evidence\": \"Co-immunoprecipitation, molecular docking, and CD73 modulation in hepatic stellate cells\",\n      \"pmids\": [\"36778123\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural interface of CD73-AURKA not validated experimentally\", \"Mechanism of ubiquitination inhibition unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CD73's enzyme-independent scaffolding functions (EGFR, AURKA, integrin, costimulatory) are structurally and mechanistically integrated with its canonical catalytic role remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking catalytic and scaffolding functions\", \"EGFR interaction rests on single Co-IP\", \"Determinants of CD73 partner selection unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 4, 23, 24]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [10, 13]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 16]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 6, 7, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 7, 10, 17]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 12]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [10, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EGFR\", \"AURKA\", \"TRIM21\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}